Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS)

Acta Clinica Belgica

Volumn 62, Issue 6, 2007, Pages 396-407

  Veys, Nic ^a,b,c   Van Biesen, W ^b   Lameire, N ^b  

^a Nephrology Department   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Algemeen Stedelijk Ziekenhuis   (Belgium)

Author keywords

Anaemia; Erythropoiesis; Erythropoiesis stimulating agents

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTINEOPLASTIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ERYTHROPOIETIN; ERYTHROPOIETIN FUSION PROTEIN; ERYTHROPOIETIN RECEPTOR; ESTERASE INHIBITOR; FG 2216; HEMOGLOBIN; HEMOPOIETIC CELL PHOSPHATASE INHIBITOR; HYBRID PROTEIN; HYPOXIA INDUCIBLE FACTOR STABILIZER; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SYNTHETIC ERYTHROPOIESIS PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ANEMIA; BLOOD BRAIN BARRIER; BLOOD PRESSURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CARDIORENAL ANEMIA SYNDROME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CRITICAL ILLNESS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MEGADOSE; ERYTHROPOIESIS; FLU LIKE SYNDROME; GENE ACTIVATION; GENE EXPRESSION; GENE THERAPY; GLOMERULUS FILTRATION RATE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEMODIALYSIS; HUMAN; HYPERTENSION; INFLAMMATION; INJECTION SITE PAIN; INTENSIVE CARE UNIT; INTERNAL MEDICINE; IRON BLOOD LEVEL; KIDNEY FAILURE; MORTALITY; NEOPLASM; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PURE RED CELL ANEMIA; QUALITY OF LIFE; RECOMBINANT DNA TECHNOLOGY; RENAL ANEMIA; REVIEW; RISK REDUCTION; SIDE EFFECT; THROMBOSIS; TREATMENT OUTCOME; VASODILATATION;

EID: 39049161068     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: 10.1179/acb.2007.059     Document Type: Review

References (103)

1. Miescher F. Ueber die Beziehungen zwischen Meereshoehe und Beschaffenheit des Blutes. Korrespbl Schweiz Arz 1893; 23: 809-30.
2. Denker BM. Erythropoietin: from bench to bedside. Nephrology Rounds at The Brigham and Women's Hospital 2004.
3. Nangaku M, Eckardt KU. Pathogenesis of renal anemia. Semin Nephrol 2006; 26: 261-8.
4. ERSLEV A. Humoral regulation of red cell production. Blood 1953; 8: 349-57.
5. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature 1985; 313: 806-10.
6. Lin FK, Suggs S, Lin CH, et al. Cloning and expression of the human erythropoietin gene. Proc Natl Acad Sci U S A 1985; 82: 7580-4.
7. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 1987; 316: 73-8.
8. Winearls CG, Oliver DO, Pippard MJ, Reid C, Downing MR, Cotes PM. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; 2: 1175-8.
9. Jelkmann W. Recombinant EPO production-points the nephrologist should know. Nephrol Dial Transplant 2007; 22: 2749-53.
10. Eckardt KU, Kurtz A. Regulation of erythropoietin production. Eur J Clin Invest 2005; 35 Suppl 3: 13-9.
11. Macdougall IC, Eckardt KU. Anemia in Chronic Kidney Disease. In: Feehally J, Floege J, Johnson RJ, eds. Comprehensive Clinical Nephrology. Mosby-Elsevier, Philadelphia: 2007; 853-60.
12. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-84.
13. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355: 2085-98.
14. Levin A. Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR. Nephrol DialTransplant 2007; 22: 309-12.
15. Berns JS, Fishbane S. CHOIR, CREATE, and anemia treatment in patients with CKD. Semin Dial 2007; 20: 277-9.
16. Beutel G, Ganser A. Risks and benefits of erythropoiesis-stimulating agents in cancer management. Semin Hematol 2007; 44: 157-65.
17. Levin A. The treatment of anemia in chronic kidney disease: understandings in 2006. Curr Opin Nephrol Hypertens 2007; 16: 267-71.
18. Remuzzi G, Ingelfinger JR. Correction of anemia - payoffs and problems. N Engl J Med 2006; 355: 2144-6.
19. Steinbrook R. Erythropoietin, the FDA, and oncology. N Engl J Med 2007; 356: 2448-51.
20. Steinbrook R. Medicare and erythropoietin. N Engl J Med 2007; 356: 4-6.
21. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: we were wrong, time to move on. Lancet 2007; 369: 346-50.
22. Collins AJ, Brenner RM, Ofman JJ, et al. Epoetin alfa use in patients with ESRD: an analysis of recent US prescribing patterns and hemoglobin outcomes. Am J Kidney Dis 2005; 46: 481-8.
23. Ishani A, Guo H, Gilbertson DT, et al. Time to target haemoglobin concentration (11 g/dl) risk of hospitalization and mortality among incident dialysis patients. Nephrol Dial Transplant 2007; 22: 2247-55.
24. Fishbane S, Berns JS. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. Kidney Int 2005; 68: 1337-43.
25. Rossert J, Froissart M. Role of anemia in progression of chronic kidney disease. Semin Nephrol 2006; 26: 283-9.
26. Cusick M, Chew EY, Hoogwerf B, et al. Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 2004; 66: 1173-9.
27. Mohanram A, Zhang Z, Shahinfar S, Keane WF, Brenner BM, Toto RD. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int 2004; 66: 1131-8.
28. Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH. Progression of nephropathy in type 2 diabetic patients. Kidney Int 2004; 66: 1596-605.
29. Furuland H, Linde T, Ahlmen J, Christensson A, Strombom U, Danielson BG. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-61.
30. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-56.
31. Rossert J, Levin A, Roger SD, et al. Effect of early correction of anemia on the progression of CKD. Am J Kidney Dis 2006; 47: 738-50.
32. Roth D, Smith RD, Schulman G, et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-84.
33. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-23.
34. Means RT, Jr. Recent developments in the anemia of chronic disease. Curr Hematol Rep 2003; 2: 116-21.
35. Ganz T. Molecular control of iron transport. J Am Soc Nephrol 2007; 18: 394-400.
36. Malyszko J, Mysliwiec M. Hepcidin in anemia and inflammation in chronic kidney disease. Kidney Blood Press Res 2007; 30: 15-30.
37. Fishbane S. Iron management in nondialysis-dependent CKD. Am J Kidney Dis 2007; 49: 736-43.
38. Hoerl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: 382-93.
39. Hoerl WH. Iron therapy for renal anemia: how much needed, how much harmful? Pediatr Nephrol 2007; 22: 480-9.
40. Corwin HL, Eckardt KU. Erythropoietin in the critically ill: what is the evidence? Nephrol Dial Transplant 2005; 20: 2605-8.
41. Corwin HL, Gettinger A, Pearl RG, et al. Efficacy of recombinant human erythropoietin in critically ill patients: a randomized controlled trial. JAMA 2002; 288: 2827-35.
42. Corwin HL, Gettinger A, Fabian TC, et al. Efficacy and safety of epoetin alfa in critically ill patients. N Engl J Med 2007; 357: 965-76.
43. Go AS, Lo JC. Epidemiology of non-dialysis-requiring chronic kidney disease and cardiovascular disease. Curr Opin Nephrol Hypertens 2006; 15: 296-302.
44. Murphy SW, Parfrey PS. Cardiac Disease in Chronic Renal Disease. In: Schrier RW, ed. Diseases of the Kidney & Urinary Tract. Wolters Kluwe/Lippincott Williams & Wilkins, Philadelphia: 2007; 2482-501.
45. Stenvinkel P, Amann K, Ketteler M. Cardiovascular Disease in Chronic Kidney Disease. In: Feehally J, Floege J, Johnson RJ, eds. Comprehensive Clinical Nephrology. Mosby-Elsevier, Philadelphia: 2007; 839-52.
46. Ritz E, Foley RN. Cardiovascular risk factors. In: Davison AM, Stewart Cameron J, Grûnfeld J-P et al, eds. Oxford Textbook of Clinical Nephrology. Oxford University Press, Oxford: 2005; 1769-89.
47. Jurkovitz C, Abramson J, McClellan WM. Anemia and cardiovascular and kidney disease. Curr Opin Nephrol Hypertens 2006; 15: 117-22.
48. Mitchell JE. Emerging role of anemia in heart failure. Am J Cardiol 2007; 99: 15D-20D.
49. Silverberg DS, Wexler D, Iaina A, Schwartz D. The interaction between heart failure and other heart diseases, renal failure, and anemia. Semin Nephrol 2006; 26: 296-306.
50. Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin. Cardiovasc Res 2003; 59: 538-48.
51. Bahlmann FH, de Groot K, Spandau JM, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004; 103: 921-26.
52. Go AS, Yang J, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113: 2713-23.
53. Silverberg DS, Wexler D, Blum M, et al. Erythropoietin in heart failure. Semin Nephrol 2005; 25: 397-403.
54. Eschbach JW. The anemia of chronic renal failure: pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35: 134-48.
55. Gill ML, Anderton JL. Erythropoietin-induced hypertension without raising haematocrit. Nephrol Dial Transplant 1993; 8: 1264-6.
56. Vaziri ND. Mechanism of erythropoietin-induced hypertension. Am J Kidney Dis 1999; 33: 821-28.
57. Erslev AJ. Erythropoietin. N Engl J Med 1991; 324: 1339-44.
58. Sundal E, Kaeser U. Correction of anemia of chronic renal failure with recombinant eryhropoietin: safey and efficacy of one year's treatment in a Euopean multicentre study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979-87.
59. Veys N, Vanholder R, De Cuyper K, Ringoir S. Influence of eythropoietin on dialyzer reuse, heparin need and urea kinetics in maintenance hemodialysis patients. Am J Kidney Dis 1994; 23: 52-9.
60. Veys N, Ringoir S. The subcutaneous administration route of epoetin: advantages, pain at the injection site and patient acceptance. Int J Artif Organs 1993; 16: 1-3.
61. Veys N, Dhondt A, Lameire N. Pain at the injetion site of subcutaneously administered erythropoietin: phosphate buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998; 49: 41-4.
62. Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16 Suppl 1: S67-S9.
63. Eckardt KU, Casadevall N. Pure red-cell aplasia due to antierythropoietin antibodies. Nephrol Dial Transplant 2003; 18: 865-9.
64. Gershon SK, Luksenburg H, Cote TR, Braun MM. Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med 2002; 346: 1584-6.
65. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002; 1: 457-62.
66. Schellekens H. Follow-on biologies: challenges of the 'next generation'. Nephrol Dial Transplant 2005; 20: iv31-iv6.
67. Bennett CL, Luminari S, Nissenson AR, et al. Pure red-cell aplasia and epoetin therapy. N Engl J Med 2004; 351: 1403-8.
68. Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrol 2007; 3: 20-30.
69. El-Achkar TM, Ohmit SE, McCullough PA, et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int 2005; 67: 1483-8.
70. Thomas MC, Weekes AJ, Broadley OJ, Cooper ME, Mathew TH. The burden of chronic kidney disease in Australian patients with type 2 diabetes (the NEFRON study). Med J Aust 2006; 185: 140-4.
71. Katavetin P, Miyata T, Inagi R, et al. High glucose blunts vascular endothelial growth factor response to hypoxia via the oxidative stress-regulated hypoxia-inducible factor/hypoxia-responsible element pathway. J Am Soc Nephrol 2006; 17: 1405-13.
72. Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-9.
73. Khuri FR. Weighing the hazards of erythropoiesis stimulation in patients with cancer. N Engl J Med 2007; 356: 2445-8.
74. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362: 1255-60.
75. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23: 5960-72.
76. Steensma DP. Erythropoiesis stimulating agents. BMJ 2007; 334: 648-9.
77. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007; 110: 477-88.
78. Lappin TR, Maxwell AP, Johnston PG. Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia. Oncologist 2007; 12: 362-5.
79. Brines M, Cerami A. Discovering erythropoietin's extra-hematopoietic functions: biology and clinical promise. Kidney Int 2006; 70: 246-50.
80. Leist M, Ghezzi P, Grasso G, et al. Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 2004; 305: 239-42.
81. Fliser D, Bahlmann FH, Haller H. EPO: renoprotection beyond anemia correction. Pediatr Nephrol 2006; 21: 1785-9.
82. Fliser D, Haller H. Erythropoietin and Treatment of Non-anemic Conditions-Cardiovascular Protection. Semin Hematol 2007; 44: 212-7.
83. Maiese K, Li F, Chong ZZ. New avenues of exploration for erythropoietin. JAMA 2005; 293: 90-5.
84. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol 2004; 207: 3233-42.
85. Cherian L, Goodman JC, Robertson C. Neuroprotection with erythropoietin administration following controlled cortical impact injury in rats. J Pharmacol Exp Ther 2007; 322: 789-94.
86. Wang Y, Zhang ZG, Rhodes K, et al. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol 2007; 151: 1377-84.
87. Celik M, Gokmen N, Erbayraktar S, et al. Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury. Proc Natl Acad Sci U S A 2002; 99: 2258-63.
88. Ehrenreich H, Hasselblatt M, Dembowski C, et al. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med 2002; 8: 495-505.
89. Erbayraktar S, Grasso G, Sfacteria A, et al. Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci U S A 2003; 100: 6741-6.
90. Erbayraktar S, de Lanerolle N, de Lotbiniere A, et al. Carbamylated erythropoietin reduces radiosurgically-induced brain injury. Mol Med 2006; 12: 74-80.
91. Tsai PT, Ohab JJ, Kertesz N, et al. A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 2006; 26: 1269-74.
92. Lipsic E, Schoemaker RG, van der Meer P, Voors AA, van Veldhuisen DJ, van Gilst WH. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 2006; 48: 2161-7.
93. Heeschen C, Aicher A, Lehmann R, et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003; 102: 1340-6.
94. Lipsic E, van der Meer P, Voors AA, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20: 135-41.
95. Macdougall IC, Eckardt KU. Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia. Lancet 2006; 368: 947-53.
96. Macdougall IC. Optimizing the use of erythropoietic agents - pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 2002; 17 Suppl 5: 66-70.
97. Macdougall IC, Padhi D, Jang G. Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 2007; 22 Suppl 4: iv2-iv9.
98. Jadoul M, Vanrenterghem Y, Foret M, Walker R, Gray SJ. Darbopoietin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients. Nephrol Dial Transplant 2004; 19: 898-903.
99. Carrera F, Disney A, Molina M. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data. Nephrol Dial Transplant 2007; 22 Suppl 4: iv19-iv30.
100. Macdougall IC. CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 2005; 4: 436-40.
101. Sulowicz W, Locatelli F, Balla J, et al. Subcutaneous (SC) C.E.R.A. (continuous erythropoietin receptor activator) administered once every 2 weeks or once monthly maintains Haemoglobin (Hb) levels in patients with chronic kidney disease (CKD) on dialysis. Nephrol Dial Transplant 2006; 21: iv156-iv57 (abstr SP424).
102. Stead R, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide TM, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood 2006; 108: 1830-4.
103. Woodburn KW, Winslow S, Leuther KK, et al. Hematide TM, a peptidic erythropoiesis stimulating agent that corrects anemia induced by partial nephrectomy and erythropoietin-specific antibodies in rats. Stockholm: European Haemotology Association meeting 2005.